Ding Y, Sheng Q J, Dou X G
Department. of Infectious Disease, Shengjing Hospital of China Medical University, Shenyang 110022, China.
Zhonghua Gan Zang Bing Za Zhi. 2019 Feb 20;27(2):85-87. doi: 10.3760/cma.j.issn.1007-3418.2019.02.002.
The main transmission route of chronic hepatitis B virus infection is mother-to-child transmission of hepatitis B virus and the main cause of combined immune prophylaxis failure in neonates at the end of pregnancy is high viral load. Moreover, oral administration of nucleos(t)ide analogues (NAs) during the second and third trimesters of pregnancy can significantly reduce or even completely block mother-to-child transmission of HBV. This article focuses on the necessity and feasibility of oral NAs antiviral therapy for HBV carrier pregnant woman with high viral load, and the issues commences at the time of medication and viral load thresholds.
慢性乙型肝炎病毒感染的主要传播途径是乙肝病毒母婴传播,妊娠末期新生儿联合免疫预防失败的主要原因是病毒载量高。此外,在妊娠中期和晚期口服核苷(酸)类似物(NAs)可显著降低甚至完全阻断HBV母婴传播。本文重点探讨了高病毒载量的HBV携带孕妇口服NAs抗病毒治疗的必要性和可行性,以及用药时机和病毒载量阈值等问题。